ReviewNeuroprotection (Chichester, England)2026
Regulatory B cells in the central nervous system: From immune regulation to neuroprotection.
Review in Neuroprotection (Chichester, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Regulatory B cells in the central nervous system: From immune regulation to neuroprotection.Neuroprotection (Chichester, England) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
This review examines the immunoregulatory functions of interleukin-10 (IL-10)-secreting regulatory B cells (Bregs), specifically focusing on their potential neuroprotective roles and therapeutic implications for central nervous system (CNS) disorders. We conducted a narrative review of the current literature to evaluate the defining characteristics, mechanisms of action, and functional significance of Bregs. We specifically analyzed their roles in modulating immune responses within the CNS following injury and in neurodegenerative contexts. Bregs are a distinct immunosuppressive B cell subset that operates primarily via IL-10 secretion. Their functions include suppressing pro-inflammatory cytokine production and directing T cell differentiation toward regulatory phenotypes. In CNS pathologies, evidence suggests that Bregs can infiltrate the blood-brain barrier following disruption. Once within the CNS, they exert neuroprotection and enhance neuronal survival, thereby mitigating post-injury inflammation. Bregs are essential to immune regulation with significant, although not fully elucidated, neuroprotective potential. Their ability to modulate CNS makes them viable therapeutic targets for the treatment of brain injuries and neurodegenerative diseases. However, clinical applications must consider the complexities of B-cell biology to avoid compromising immune homeostasis. Further research into Breg mechanisms is vital for developing safe, targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.